Latest News
REGENXBIO Inc.
- REGENXBIO convenes retina specialists as Phase 3 sura-vec data approaches
- REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy
- Regenxbio Inc. Announces Board Changes, Effective October 21, 2026
- Regenxbio, Penn End Revived Sarepta Gene-Therapy Patent Fight
- REGENXBIO’s diabetic eye gene therapy reaches three-year mark
- Full Transcript: Regenxbio Q2 2026 Earnings Call
- Mizuho initiates Regenxbio stock coverage with outperform rating
- Why is Regenxbio stock climbing today?
- REGENXBIO reports three-year ALTITUDE DRSS data
- Stifel reiterates Regenxbio stock rating on gene therapy data
- Sarepta Settles Regenxbio’s Patent Infringement Claims in $39M Deal
- Sarepta to pay Regenxbio $39M to settle gene therapy claims; Vida eyes fourth fund
Headlines from the last 30 days, linking to the original publishers. See all market news →